ProQR finds eye disease partner in Europe, hands off two late-stage candidates
ProQR has inked a deal with French company Laboratoires Théa and transferring two late-stage candidates to the company in a deal worth up to €147.5 million, or about $162 million.
The companies made the joint announcement Tuesday that Théa gets its hands on two single-strand oligonucleotide candidates, sepofarsen and ultevursen — paying €12.5 million, or roughly $13.7 million up front. ProQR noted the company is eligible for another €135 million, approximately $148 million, from Théa in more development, regulatory and commercial payments, plus royalties.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
